Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Aurinia Pharmaceuticals Inc. (AUPH)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Dec-31-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21Jun-30-21Mar-31-21
   10-Q8-K10-Q10-Q10-K10-Q10-Q10-Q
Revenue          
Total revenue, net  41.528.428.221.623.414.76.60.9
            Total revenue, net growth  47.2%21.5%325.8%2266.0%-53.2%50475.9%-40.4%2946.7%
Operating expenses          
Cost of sales  1.61.41.60.30.50.30.30.0
Selling, general and administrative  47.1 51.545.246.344.144.339.8
Research and development  12.79.911.512.611.120.110.19.8
Other (income) expense, net  -3.6-2.2-0.51.4-0.30.1-1.01.8
    Total cost of sales and operating expenses  57.756.564.259.556.165.053.851.5
    Loss from operations  -16.2-28.1-36.0-37.9-32.7-50.4-47.1-50.5
            Operating margin  -39.0%-98.8%-127.7%-175.2%-139.7%-343.3%-712.0%-5529.9%
Interest expense  -0.1       
Interest income  4.12.90.50.30.10.10.10.2
    Net loss before income taxes  -12.1 -35.5-37.6-32.6-50.2-47.0-50.4
Income tax (benefit) expense  -0.60.90.00.00.70.00.00.0
    Net loss  -11.5-26.0-35.5-37.6-33.3-50.3-47.0-50.4
   
Other comprehensive loss:          
Unrealized (loss) gain on available-for-sale securities, net of tax of nil  0.0 -0.2-0.8-0.10.00.00.0
    Comprehensive loss  -11.5 -35.8-38.4-33.4-50.3-47.0-50.4
   
Basic loss per share (in usd per share)  ($0.08)($0.18)($0.25)($0.27)($0.25)($0.39)($0.37)($0.40)
Diluted loss per share (in usd per share)  ($0.08)($0.18)($0.25)($0.27)($0.25)($0.39)($0.37)($0.40)
   
Weighted-average common shares outstanding used in computation of basic loss per share  142.8141.9141.7141.7129.4128.4128.2127.4
Weighted-average common shares outstanding used in computation of diluted loss per share  142.8141.9141.7141.7129.4128.4128.2127.4

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy